A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Inclusion Criteria:

• Participants with the ability to understand the requirements of the trial, providewritten informed consent, and comply with the trial protocol procedures.

• Male or female participants aged ≥ 18 years.

• Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.

• Other, more specific inclusion criteria are defined in the protocol.

Exclusion Criteria:

• Have previously been successfully treated with radioactive iodine (RAI) therapy orhave undergone total thyroidectomy.

• Have an autoimmune disease other than GD requiring treatment that, in theInvestigator's judgment, puts the participant at undue risk.

• Have moderate-to-severe active thyroid eye disease (TED) and are expected to requireimmediate surgical intervention and/or are planning corrective surgery/irradiationor medical therapy for TED during study participation.

• Additional exclusion criteria are defined in the protocol.